Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 13/30237% above fair value
$111.60−2.62 (-2.29%)
Close on Nov 13, 2026Market cap $7.00BP/E –Yield –
Twist Bioscience ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Twist Bioscience's ebitda for the twelve months ending Jun 30, 2026 was -$119.59M. For fiscal 2025 it was -$111.41M. The highest annual figure on record is -$53.46M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$111.41M | – |
| FY2024 | Sep 30, 2024 | -$189.40M | – |
| FY2023 | Sep 30, 2023 | -$187.85M | – |
| FY2022 | Sep 30, 2022 | -$218.26M | – |
| FY2021 | Sep 30, 2021 | -$142.98M | – |
| FY2020 | Sep 30, 2020 | -$133.40M | – |
| FY2019 | Sep 30, 2019 | -$102.74M | – |
| FY2018 | Sep 30, 2018 | -$64.83M | – |
| FY2017 | Sep 30, 2017 | -$53.46M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$29.50M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$39.45M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$26.71M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$23.93M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$24.06M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$35.16M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$28.26M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$29.39M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$80.62M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$40.59M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$38.81M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$41.61M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$52.29M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$54.61M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$39.34M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$51.92M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$56.72M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$56.83M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$52.79M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$37.38M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$39.37M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$35.54M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$30.68M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$22.08M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$26.47M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$30.53M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$54.33M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$30.08M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$26.53M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$24.70M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$21.43M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$18.38M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$15.79M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$15.20M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$15.47M | – |
See a number that looks wrong?